957211-40-4

Upstream product

• 957211-39-1 C₉H₇Br₂ClO 
• 957211-38-0 trimethyl-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-stannane 
• 957211-48-2 2-(2,6-dibromo-benzyl)-3-oxo-3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-propionic acid ethyl ester 

Downstream Products

• 957211-41-5 3-(2,6-dibromo-phenyl)-1-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-propan-1-ol 
• 957212-65-6 (αR)-2,6-dibromo-α-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]benzenepropanol 
• 957212-54-3 (αS)-2,6-dibromo-α-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]benzenepropanol 

Relevant academic research and scientific papers

Improved asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2- tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-α- (trifluoromethyl)-1(2H)-quinolineethanol, a potent cholesteryl ester transfer protein inhibitor

The asymmetric synthesis of 3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy) phenyl]-5-[3-(trifluoromethoxy)phenyl]-α-(trifluoromethyl)-1(2H) -quinolineethanol (compound 11), a cholesteryl ester transfer protein inhibitor, Is accomplished. The asymmetric cent

Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform

Tetrahydroquinoline A is a potent inhibitor of the cholesterol ester transfer protein (CETP), a target for the treatment of low HDL-C and atherosclerosis. Low HDL-C has been identified as a key risk factor for cardiovascular disease in addition to high LD

Design, synthesis, and biological evaluation of (2R,αS)-3,4-dihydro- 2-[3-(1,1,2,2-tetrafluoroet-hoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl] -a-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibi

With the goal of identifying a CETP inhibitor with high in vitro potency and optimal in vivo efficacy, a conformationally constrained molecule was designed based on the highly potent and flexible 13. The synthetic chemistry efforts led to the discovery of

1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS

The invention is directed to compounds of Formula (I) described herein useful as CETP inhibitors, compositions containing them, and methods of using them.